Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
- Published In:
- Lancet (London, England), 398(10317), 2160-2172 (2021)
- Authors:
- Lau, David C W(2), Erichsen, Lars, Francisco, Ann Marie, Satylganova, Altynai, le Roux, Carel W, McGowan, Barbara, Pedersen, Sue D, Pietiläinen, Kirsi H, Rubino, Domenica, Batterham, Rachel L
- Database ID:
- RPEP-05529
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-05529APA
Lau, David C W; Erichsen, Lars; Francisco, Ann Marie; Satylganova, Altynai; le Roux, Carel W; McGowan, Barbara; Pedersen, Sue D; Pietiläinen, Kirsi H; Rubino, Domenica; Batterham, Rachel L. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.. Lancet (London, England), 398(10317), 2160-2172. https://doi.org/10.1016/S0140-6736(21)01751-7
MLA
Lau, David C W, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.." Lancet (London, 2021. https://doi.org/10.1016/S0140-6736(21)01751-7
RethinkPeptides
RethinkPeptides Research Database. "Once-weekly cagrilintide for weight management in people wit..." RPEP-05529. Retrieved from https://rethinkpeptides.com/research/lau-2021-onceweekly-cagrilintide-for-weight
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.